CaroGen Corporation
Farmington, US · Founded 2012 · 10 employees on LinkedIn · 1 known investors
Find your way into CaroGen Corporation
107 people in our graph share verified history with the CaroGen Corporation team — schools, employers, funds. One of them is your warm intro.
Kevin Crowleyunlockedknows Valerian Nakaar · together at CaroGen Corporation (overlapped)
×6knows the team · via Yale University School of Medicine
×5knows the team · via Weizmann Institute of Science
CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.
Founders & leadership
CaroGen Corporation was founded in 2012 by Bijan Almassian.
BA
Bijan AlmassianinCEOBijan Almassian is the co-founder and CEO of CaroGen Corporation, a biotechnology company spun out of Yale School of Medicine that develops virus-like vesicle (VLV) immunotherapies for cancer and chronic infections. He has decades of experience in life science company formation, venture strategy, licensing, intellectual property development, and translational medicine, and currently focuses on advancing immunotherapies such as CARG-2020 aimed at preventing cancer recurrence.
VN
Valerian NakaarinChief Scientific Officer & Board MemberChief Scientific Officer and board member of CaroGen Corporation, which develops immunotherapies for cancer and infectious diseases using an enveloped self-amplifying mRNA platform.
DC
Deborah ChurchChief Medical Officer
KL
King LeeVP, Regulatory Affairs
TY
Timur YarovinksyVP, Discovery
JR
Joseph RiningerVP, Product Development
Investors · 1
Competitors · 5
by search overlap
Biogen Idec19 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Compugen14 shared keywordsCompugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
Wugen14 shared keywordsAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
Cullgen12 shared keywordsCullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.
Precigen11 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
Companies competing with CaroGen Corporation for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does CaroGen Corporation do?
- CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.
- Who founded CaroGen Corporation?
- CaroGen Corporation was founded by Bijan Almassian in 2012.
- Who are CaroGen Corporation's investors?
- CaroGen Corporation's investors include Connecticut Innovations.
- Where is CaroGen Corporation headquartered?
- CaroGen Corporation is headquartered in Farmington, US.